These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19762110)

  • 1. Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
    Waller LL; Miller AA; Petty WJ
    Lung Cancer; 2010 Jan; 67(1):12-6. PubMed ID: 19762110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
    Gadgeel SM
    Clin Lung Cancer; 2006 May; 7(6):369-70. PubMed ID: 16800960
    [No Abstract]   [Full Text] [Related]  

  • 3. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
    Hughes AN; O'Brien ME; Petty WJ; Chick JB; Rankin E; Woll PJ; Dunlop D; Nicolson M; Boinpally R; Wolf J; Price A
    J Clin Oncol; 2009 Mar; 27(8):1220-6. PubMed ID: 19164205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
    Reckamp KL; Gardner BK; Figlin RA; Elashoff D; Krysan K; Dohadwala M; Mao J; Sharma S; Inge L; Rajasekaran A; Dubinett SM
    J Thorac Oncol; 2008 Feb; 3(2):117-24. PubMed ID: 18303430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
    Lind JS; Postmus PE; Heideman DA; Thunnissen EB; Bekers O; Smit EF
    J Thorac Oncol; 2009 Dec; 4(12):1585-6. PubMed ID: 20009914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
    Clark GM; Zborowski DM; Culbertson JL; Whitehead M; Savoie M; Seymour L; Shepherd FA
    J Thorac Oncol; 2006 Oct; 1(8):837-46. PubMed ID: 17409968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
    Arrieta O; Martinez-Barrera L; Treviño S; Guzman E; Castillo-Gonzalez P; Rios-Trejo MA; Flores-Estrada D; Téllez E; Gonzalez C; de la Cruz Vargas J; Gonzalez-De la Rosa CH; Hernandez-Pedro N; Morales-Barrera R; De la Garza J
    J Thorac Oncol; 2008 Aug; 3(8):887-93. PubMed ID: 18670307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
    Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
    J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
    Muir VJ; Dhillon S
    BioDrugs; 2011 Jun; 25(3):139-46. PubMed ID: 21513367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
    Togashi Y; Masago K; Fukudo M; Terada T; Ikemi Y; Kim YH; Fujita S; Irisa K; Sakamori Y; Mio T; Inui K; Mishima M
    J Thorac Oncol; 2010 May; 5(5):601-5. PubMed ID: 20234322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
    Cioffi P; Marotta V; Fanizza C; Giglioni A; Natoli C; Petrelli F; Grappasonni I
    J Oncol Pharm Pract; 2013 Sep; 19(3):246-53. PubMed ID: 23223401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
    Florescu M; Hasan B; Seymour L; Ding K; Shepherd FA;
    J Thorac Oncol; 2008 Jun; 3(6):590-8. PubMed ID: 18520796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.